CEO of U.S. Rare Disease Biotech Plans to Sell $100 Million in Company Shares

BridgeBio Pharma, Inc. (NASDAQ: BBIO) CEO Neil Kumar, under a Rule 10b5-1 trading plan established for succession planning and estate design, automatically sold 80,000 common shares through a family trust on April 9–10, 2026, generating approximately $5.97 million (KRW 8 billion). He then executed an additional sale of 80,000 shares through two trusts on May 7–8 under the same plan, raising roughly $5.4–$5.5 million (about KRW 7 billion). Both transactions involved partial dispositions of his existing holdings, as disclosed. Following these trades, the trusts associated with CEO Kumar hold about 4.91 million shares, while Kumar personally retains approximately 230,000 shares, maintaining a significant economic stake in the company’s stock performance.

In its first-quarter 2026 results announced on May 7, BridgeBio reported revenues of $194.5 million, driven by strong sales of its ATTR-CM therapy, Attruby. The company also filed a New Drug Application for BBP-418 in the U.S. and outlined regulatory timelines and clinical plans for additional rare-disease assets in its pipeline. On May 6, the board approved a share repurchase program of up to $500 million (approximately KRW 700 billion). Several global securities firms have raised their price targets on BBIO and expanded coverage, citing the company’s robust performance and pipeline.

Headquartered in Palo Alto, California, BridgeBio Pharma is a developer of genetic and rare-disease therapeutics. Its portfolio includes the ATTR-CM treatment acoramidis (brand name Attruby) and several late-stage clinical candidates for conditions such as spinal muscular atrophy and hypoparathyroidism. Founder and CEO Neil Kumar has retained a significant ownership stake since the company’s IPO through a combination of family trusts and direct holdings; this recent disclosure reflects a planned sale under that established ownership structure.